

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 468 520 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91112601.9


(51) Int. Cl.⁵: **A61K 31/70**

(22) Date of filing: 26.07.91

(30) Priority: 27.07.90 JP 197778/90

(43) Date of publication of application:
29.01.92 Bulletin 92/05(64) Designated Contracting States:
DE FR GB IT(68) Date of deferred publication of the search report:
01.07.92 Bulletin 92/27(71) Applicant: **MITSUI TOATSU CHEMICALS, Inc.**
2-5 Kasumigaseki 3-chome
Chiyoda-Ku Tokyo 100(JP)(72) Inventor: **Tokunaga, Tohru**
1-9-7, Horinouchi
Suginami-ku, Tokyo(JP)
Inventor: **Kataoka, Tetsuro**
2-47-10, Hijirigaoka**Tama-shi, Tokyo(JP)**Inventor: **Yamamoto, Saburo****4-1-18, Naka-machi****Koganei-shi, Tokyo(JP)**Inventor: **Kuramoto, Etsuro****Miyanodal-Aparto 640-15, 2141, Tougou****Mobara-shi, Chiba-ken(JP)**Inventor: **Yano, Osamu****Miyanodal-daini-aparto 740-11, 2142, Tougou****Mobara-shi, Chiba-ken(JP)**Inventor: **Shimada, Shizuo****Miyanodal-aparto 640-35, 2141, Tougou****Mobara-shi, Chiba-ken(JP)**Inventor: **Makino, Tadashi****5-14-8, Hiyoshidai****Togane-shi, Chiba-ken(JP)**(74) Representative: **Vossius & Partner**
Siebertstrasse 4 P.O. Box 86 07 67
W-8000 München 86(DE)(54) **Immunostimulatory remedies containing palindromic DNA sequences.**

(57) Single-stranded, linear polydeoxyribonucleotides with a base number of 10 to 100 containing at least one structure represented by the following general formula:



(wherein n is an integer from 3 to 50; X_1 , X_2 , X_3 , \cdots , X_n and Y_1 , Y_2 , Y_3 , \cdots , Y_n are each a monodeoxyribonucleotide; X_1 , X_2 , X_3 , \cdots and X_n may be the same or different nucleotides; and bases in X_1 and Y_1 , in X_2 and Y_2 , in X_3 and Y_3 , in \cdots , and in X_n and Y_n are complementary with each other as defined by Watson & Crick), and double-stranded, linear polydeoxyribonucleotides, in which at least one single-stranded, linear polydeoxyribonucleotide contains at least one structure represented by the general formula (I), both show strong immunostimulatory activity.

Thus, remedies containing, as active ingredient, such a specific polydeoxyribonucleotide as described

above, or a salt thereof, are efficacious against malignant tumors, infectious diseases, immunodeficiency diseases and autoimmune diseases, with minimized side-effects.

EP 0 468 520 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 11 2601

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
X	EP-A-0 300 687 (CITY OF HOPE) * page 2, line 48 - line 49 *	1-2	A61K31/70
X	EP-A-0 302 758 (NEW ENGLAND MEDICAL CENTER HOSPITALS) * claims 2-4 *	1-2	
X	DE-A-3 744 785 (THEURER K.) * the whole document *	1-2	
A	WORLD PATENTS INDEX LATEST Week 9026, Derwent Publications Ltd., London, GB; AN 90-196689 & JP-A-2 128 691 (NIPPON OIL SEAL) 17 May 1990 * abstract *	1-21	
A,P	MEDLINE ABSTRACT Number: 90338013 WEGNER M. et al: "Interaction of a protein with a palindromic sequence from murine RDNA increases the occurrence of amplification-dependent transformation in mouse cells." & J.BIOL.CHEM. 15 august 1990, 265 (23), p 13925-32	1-21	
			TECHNICAL FIELDS SEARCHED (Int. CL.5)
			A61K
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 22 APRIL 1992	Examiner AVEDIKIAN P. F.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			